Correction: Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor (Journal of Medicinal Chemistry (2014) 57 (6458−6467) DOI: 10.1021/jm500802j);Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor

Journal of Medicinal Chemistry

Volumn 57, Issue 15, 2014, Pages 6458-6467

  Li, Huifang ^a   Ban, Fuqiang ^a   Dalal, Kush ^a   Leblanc, Eric ^a   Frewin, Kate ^a   Ma, Dennis ^a   Adomat, Hans ^a   Rennie, Paul S ^a   Cherkasov, Artem ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUORO 6 (2 MORPHOLINOTHIAZOL 4 YL)PHENOL; 2,3 DIFLUORO 6 (2 MORPHOLINOTHIAZOL 4 YL)PHENOL; 3 FLUORO 4 METHOXY 5 (2 MORPHOLINOTHIAZOL 4 YL)PHENOL; 4 (5 METHYL 4 PHENYLTHIAZOL 2 YL)MORPHOLINE; 4 [4 (3 FLUORO 2 METHANESULFONYL PHENYL) THIAZOL 2 YL]MORPHOLINE; 4 [4 (4 BROMO 1H IMIDAZOL 1 YL)THIAZOL 2 YL]MORPHOLINE; 4 [4 (4 BROMO 5 CHLORO 1H IMIDAZOL 1 YL)THIAZOL 2 YL]MORPHOLINE; 4 [4 (4 CHLORO 5 IODO 1H IMIDAZOL 1 YL]THIAZOL 2 YL]MORPHOLINE; 4 [4 (4 FLUORO 2 METHOXYPHENYL)THIAZOL 2 YL]MORPHOLINE; 4 [4 (4,5 DIBROMO 1H IMIDAZOL 1 YL)THIAZOL 2 YL]MORPHOLINE; 4 [4 (4,5 DICHLORO 1H IMIDAZOL 1 YL)THIAZOL 2 YL]MORPHOLINE; 4 [4 (4,5 DIIODO 1H IMIDAZOL 1 YL)THIAZOL 2 YL]MORPHOLINE; 4 [4 (4,5 DIMETHYL 1H IMIDAZOL 1 YL)THIAZOL 2 YL]MORPHOLINE; 4 [4 (4,5 DIMETHYLTHIOPHE 3 YL)THIAZOL 2 YL]MORPHOLINE; 4 [4 (5 BROMO 4 CHLORO 1H IMIDAZOL 1 YL)THIAZOL 2 YL]MORPHOLINE; 4 [4 (PYRIDINE 4 YL)THIAZOL 2 YL]MORPHOLINE; 4 [4 (THIOPHEN 3 YL)THIAZOL 2 YL]MORPHOLINE; 4 [4 [4 CHLORO 1H IMIDAZOL 1 YL)THIAZOL 2 YL]MORPHOLINE; 5 FLUORO 2 (2 MORPHOLINOTHIAZOL 4 YL)PHENOL; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROGEN RECEPTOR DNA BINDING DOMAIN INHIBITOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DNA; ENZALUTAMIDE; MORPHOLINE DERIVATIVE; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; [4 4 (3,4 DIFLUORO 2 METHOXYPHENYL)THIAZOL 2 YL]MORPHOLINE; 4-(4-(4,5-DIBROMO-1H-IMIDAZOL-1-YL)THIAZOL-2-YL)MORPHOLINE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PHENYLTHIOHYDANTOIN; PROSTATE SPECIFIC ANTIGEN; PYRVINIUM EMBONATE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; MALE; PROTEIN FOLDING; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMICAL DATABASE; CHEMISTRY; COMPUTER SIMULATION; CONFORMATION; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULAR DOCKING; MUTATION; PROSTATIC NEOPLASMS; RAT; SECRETION (PROCESS); SYNTHESIS; TUMOR CELL LINE;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; COMPUTER SIMULATION; DATABASES, CHEMICAL; DNA; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; MALE; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; MORPHOLINES; MUTATION; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRVINIUM COMPOUNDS; RATS; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIOPHENES; TRANSCRIPTION, GENETIC;

EID: 84906080748     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b00005     Document Type: Erratum

References (45)

1. Attard, G.; Richards, J.; de Bono, J. S. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway Clin. Cancer Res. 2011, 17, 1649-1657
2. Decker, K. F.; Zheng, D.; He, Y.; Bowman, T.; Edwards, J. R.; Jia, L. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions Nucleic Acids Res. 2012, 40, 10765-10779
3. de Bono, J. S.; Logothetis, C. J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K. N.; Jones, R. J.; Goodman, O. B., Jr.; Saad, F.; Staffurth, J. N.; Mainwaring, P.; Harland, S.; Flaig, T. W.; Hutson, T. E.; Cheng, T.; Patterson, H.; Hainsworth, J. D.; Ryan, C. J.; Sternberg, C. N.; Ellard, S. L.; Flechon, A.; Saleh, M.; Scholz, M.; Efstathiou, E.; Zivi, A.; Bianchini, D.; Loriot, Y.; Chieffo, N.; Kheoh, T.; Haqq, C. M.; Scher, H. I. Abiraterone and increased survival in metastatic prostate cancer N. Engl. J. Med. 2011, 364, 1995-2005
4. Scher, H. I.; Fizazi, K.; Saad, F.; Taplin, M. E.; Sternberg, C. N.; Miller, K.; de Wit, R.; Mulders, P.; Chi, K. N.; Shore, N. D.; Armstrong, A. J.; Flaig, T. W.; Flechon, A.; Mainwaring, P.; Fleming, M.; Hainsworth, J. D.; Hirmand, M.; Selby, B.; Seely, L.; de Bono, J. S. Increased survival with enzalutamide in prostate cancer after chemotherapy N. Engl. J. Med. 2012, 367, 1187-1197
5. Hoffman-Censits, J.; Kelly, W. K. Enzalutamide: a novel anti-androgen for patients with castrate resistant prostate cancer Clin. Cancer Res. 2013, 19, 1335-1339
6. Bohl, C. E.; Gao, W.; Miller, D. D.; Bell, C. E.; Dalton, J. T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 6201-6206
7. Bohl, C. E.; Miller, D. D.; Chen, J.; Bell, C. E.; Dalton, J. T. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor J. Biol. Chem. 2005, 280, 37747-37754
8. Balbas, M. D.; Evans, M. J.; Hosfield, D. J.; Wongvipat, J.; Arora, V. K.; Watson, P. A.; Chen, Y.; Greene, G. L.; Shen, Y.; Sawyers, C. L. Overcoming mutation-based resistance to antiandrogens with rational drug design Elife 2013, 2, e00499
9. Scher, H. I.; Beer, T. M.; Higano, C. S.; Anand, A.; Taplin, M. E.; Efstathiou, E.; Rathkopf, D.; Shelkey, J.; Yu, E. Y.; Alumkal, J.; Hung, D.; Hirmand, M.; Seely, L.; Morris, M. J.; Danila, D. C.; Humm, J.; Larson, S.; Fleisher, M.; Sawyers, C. L. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 2010, 375, 1437-1446
10. Li, Y.; Chan, S. C.; Brand, L. J.; Hwang, T. H.; Silverstein, K. A.; Dehm, S. M. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines Cancer Res. 2012, 73, 483-489
11. Watson, P. A.; Chen, Y. F.; Balbas, M. D.; Wongvipat, J.; Socci, N. D.; Viale, A.; Kim, K.; Sawyers, C. L. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 16759-16765
12. Dehm, S. M.; Tindall, D. J. Alternatively spliced androgen receptor variants Endocr.-Relat. Cancer 2011, 18, R183-R196
13. Li, Y.; Alsagabi, M.; Fan, D.; Bova, G. S.; Tewfik, A. H.; Dehm, S. M. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression Cancer Res. 2011, 71, 2108-2117
14. Chan, S. C.; Li, Y.; Dehm, S. M. Androgen receptor splice variants activate AR target genes and support aberrant prostate cancer cell growth independent of the canonical AR nuclear localization signal J. Biol. Chem. 2012, 23, 19736-19749
15. Hu, R.; Lu, C. X.; Mostaghel, E. A.; Yegnasubramanian, S.; Gurel, M.; Tannahill, C.; Edwards, J.; Isaacs, W. B.; Nelson, P. S.; Bluemn, E.; Plymate, S. R.; Luo, J. Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer Cancer Res. 2012, 72, 3457-3462
16. van Royen, M. E.; van Cappellen, W. A.; de Vos, C.; Houtsmuller, A. B.; Trapman, J. Stepwise androgen receptor dimerization J. Cell Sci. 2012, 125, 1970-1979
17. Luisi, B. F.; Xu, W. X.; Otwinowski, Z.; Freedman, L. P.; Yamamoto, K. R.; Sigler, P. B. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA Nature 1991, 352, 497-505
18. Schwabe, J. W. R.; Chapman, L.; Finch, J. T.; Rhodes, D. The Crystal-Structure of the Estrogen-Receptor DNA-Binding Domain Bound to DNA-How Receptors Discriminate between Their Response Elements Cell 1993, 75, 567-578
19. Shaffer, P. L.; Jivan, A.; Dollins, D. E.; Claessens, F.; Gewirth, D. T. Structural basis of androgen receptor binding to selective androgen response elements Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 4758-4763
20. Roemer, S. C.; Donham, D. C.; Sherman, L.; Pon, V. H.; Edwards, D. P.; Churchill, M. E. Structure of the progesterone receptor-deoxyribonucleic acid complex: novel interactions required for binding to half-site response elements Mol. Endocrinol. 2006, 20, 3042-3052
21. Khorasanizadeh, S.; Rastinejad, F. Nuclear-receptor interactions on DNA-response elements Trends Biochem. Sci. 2001, 26, 384-390
22. Nickols, N. G.; Dervan, P. B. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 10418-10423
23. Jones, J. O.; Bolton, E. C.; Huang, Y.; Feau, C.; Guy, R. K.; Yamamoto, K. R.; Hann, B.; Diamond, M. I. Non-competitive androgen receptor inhibition in vitro and in vivo Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 7233-7238
24. Liang, J.; Edelsbrunner, H.; Woodward, C. Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design Protein Sci. 1998, 7, 1884-1897
25. Irwin, J. J.; Shoichet, B. K. ZINC-a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45, 177-182
26. Tavassoli, P.; Snoek, R.; Ray, M.; Rao, L. G.; Rennie, P. S. Rapid, non-destructive, cell-based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells Prostate 2007, 67, 416-426
27. Zhuang, C.; Narayanapillai, S.; Zhang, W.; Sham, Y. Y.; Xing, C. Rapid Identification of Keap1-Nrf2 Small-Molecule Inhibitors through Structure-Based Virtual Screening and Hit-Based Substructure Search J. Med. Chem. 2014, 57 (3) 1121-1126
28. Kuruma, H.; Matsumoto, H.; Shiota, M.; Bishop, J.; Lamoureux, F.; Thomas, C.; Briere, D.; Los, G.; Gleave, M.; Fanjul, A.; Zoubeidi, A. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo Mol. Cancer Ther. 2013, 12, 567-576
29. Snoek, R.; Bruchovsky, N.; Kasper, S.; Matusik, R. J.; Gleave, M.; Sato, N.; Mawji, N. R.; Rennie, P. S. Differential transactivation by the androgen receptor in prostate cancer cells Prostate 1998, 36, 256-263
30. Dalal, K.; Moniri, M.; Sharma, A.; Li, H.; Ban, F.; Hessein, M.; Hsing, M.; Singh, K.; Leblanc, E.; Dehm, S.; Guns, E. T.; Cherkasov, A.; Rennie, P. S. Selectively Targeting the DNA Binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer 2014.
31. Axerio-Cilies, P.; Lack, N. A.; Nayana, M. R.; Chan, K. H.; Yeung, A.; Leblanc, E.; Guns, E. S.; Rennie, P. S.; Cherkasov, A. Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening J. Med. Chem. 2011, 54, 6197-6205
32. Estebanez-Perpina, E.; Arnold, A. A.; Nguyen, P.; Rodrigues, E. D.; Mar, E.; Bateman, R.; Pallai, P.; Shokat, K. M.; Baxter, J. D.; Guy, R. K.; Webb, P.; Fletterick, R. J. A surface on the androgen receptor that allosterically regulates coactivator binding Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 16074-16079
33. Munuganti, R. S.; Leblanc, E.; Axerio-Cilies, P.; Labriere, C.; Frewin, K.; Singh, K.; Hassona, M. D.; Lack, N. A.; Li, H.; Ban, F.; Tomlinson Guns, E.; Young, R.; Rennie, P. S.; Cherkasov, A. Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl)thio)-1 H-benzimidazole Derivatives J. Med. Chem. 2013, 56, 1136-1148
34. Lack, N. A.; Axerio-Cilies, P.; Tavassoli, P.; Han, F. Q.; Chan, K. H.; Feau, C.; Leblanc, E.; Guns, E. T.; Guy, R. K.; Rennie, P. S.; Cherkasov, A. Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening J. Med. Chem. 2011, 54, 8563-8573
35. Caboni, L.; Kinsella, G. K.; Blanco, F.; Fayne, D.; Jagoe, W. N.; Carr, M.; Williams, D. C.; Meegan, M. J.; Lloyd, D. G. "True" Antiandrogens-Selective Non-Ligand-Binding Pocket Disruptors of Androgen Receptor-Coactivator Interactions: Novel Tools for Prostate Cancer J. Med. Chem. 2012, 55, 1635-1644
36. Li, H.; Hassona, M. D.; Lack, N. A.; Axerio-Cilies, P.; Leblanc, E.; Tavassoli, P.; Kanaan, N.; Frewin, K.; Singh, K.; Adomat, H.; Bohm, K. J.; Prinz, H.; Guns, E. T.; Rennie, P. S.; Cherkasov, A. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer Mol. Cancer Ther. 2013, 12, 2425-2435
37. Li, H.; Ren, X.; Leblanc, E.; Frewin, K.; Rennie, P. S.; Cherkasov, A. Identification of novel androgen receptor antagonists using structure-and ligand-based methods J. Chem. Inf. Model. 2013, 53, 123-130
38. Lim, M.; Otto-Duessel, M.; He, M.; Su, L.; Nguyen, D.; Chin, E.; Alliston, T.; Jones, J. O. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium ACS Chem. Biol. 2013, 9, 692-702
39. Zilliacus, J.; Wright, A. P.; Carlstedt-Duke, J.; Gustafsson, J. A. Structural determinants of DNA-binding specificity by steroid receptors Mol. Endocrinol. 1995, 9, 389-400
40. Claessens, F.; Alen, P.; Devos, A.; Peeters, B.; Verhoeven, G.; Rombauts, W. The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors J. Biol. Chem. 1996, 271, 19013-19016
41. Denayer, S.; Helsen, C.; Thorrez, L.; Haelens, A.; Claessens, F. The rules of DNA recognition by the androgen receptor Mol. Endocrinol. 2010, 24, 898-913
42. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
43. Ritchie, T. J.; Macdonald, S. J. The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design? Drug Discovery Today 2009, 14, 1011-1020
44. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
45. Lack, N. A.; Axerio-Cilies, P.; Tavassoli, P.; Han, F. Q.; Chan, K. H.; Feau, C.; Leblanc, E.; Guns, E. T.; Guy, R. K.; Rennie, P. S.; Cherkasov, A. Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening J. Med. Chem. 2011, 55, 8563-8573